SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma

NEXT STORY
G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
PREV STORY
Worldwide Travel Vaccines Industry to 2025 – Key Drivers, Challenges and Trends
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medical Mask Market to Grow at 8.5% CAGR and Touch USD 2.15 Billion by 2027; Driven by Growing Investments in Product Manufacturing, says Fortune Business Insights™

author_avatar
NASDAQ Market News

Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

author_avatar
NASDAQ Market News

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

author_avatar
NASDAQ Market News